Related Experiment Video
Updated: Jul 11, 2025
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Metronomic chemotherapy in ovarian cancer
1Clinical Research Fellow, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Avenue, 7th Floor, Station 7W386, M5G 1Z5, Toronto, ON, Canada.
Abstract:
Translational research and the development of targeted therapies have transformed the therapeutic landscape in epithelial ovarian cancer over the last decade. However, recurrent ovarian cancer continues to pose formidable challenges to therapeutic interventions, necessitating innovative strategies to optimize treatment outcomes. Current research focuses on the development of pharmaceuticals that target potential resistance pathways to DNA repair pathways. However, the cost and toxicity of some of these therapies are prohibitive and majority of patients lack access to clinical trials. Metronomic chemotherapy, characterized by the continuous administration of low doses of chemotherapeutic agents without long treatment breaks, has emerged as a promising approach with potential implications beyond recurrent setting. It acts primarily by inhibition of angiogenesis and activation of host immune system. We here review the mechanism of action of metronomic chemotherapy, as well as its current role, limitations, and avenues for further research in the management of epithelial ovarian cancer.
Insights
Metronomic chemotherapy offers a promising, low-cost strategy for recurrent ovarian cancer by inhibiting angiogenesis and boosting the immune system. This approach may improve treatment outcomes and accessibility for patients.
Area of Science:
- Oncology
- Cancer Therapeutics
- Translational Research
Background:
- Epithelial ovarian cancer treatment has advanced with targeted therapies, but recurrence remains challenging.
- Existing therapies face limitations due to cost, toxicity, and limited clinical trial access.
- Novel strategies are crucial for optimizing treatment outcomes in recurrent ovarian cancer.
Purpose of the Study:
- To review the mechanism of action of metronomic chemotherapy.
- To explore the current role and limitations of metronomic chemotherapy in epithelial ovarian cancer.
- To identify future research directions for metronomic chemotherapy in ovarian cancer management.
Main Methods:
- Literature review on metronomic chemotherapy.
- Analysis of its application in epithelial ovarian cancer.
- Examination of its mechanisms, including anti-angiogenesis and immune activation.
Main Results:
- Metronomic chemotherapy involves continuous low-dose chemotherapy without long breaks.
- It primarily functions by inhibiting angiogenesis and activating the host immune system.
- This approach presents a potential alternative for recurrent ovarian cancer, addressing cost and accessibility issues.
Conclusions:
- Metronomic chemotherapy is a viable strategy for epithelial ovarian cancer, particularly in the recurrent setting.
- Further research is needed to fully elucidate its potential and optimize its application.
- It offers a promising avenue for improving patient outcomes and treatment accessibility.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...